Sigma Planning’s Palvella Therapeutics PVLA Stock Holding History
Bought
Maintained
Sold
Other funds holding PVLA
Sigma Planning's PVLA Position: Q1 2026 in Review
Sigma Planning sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 6,500 shares — an estimated $680K sold.
Sigma Planning first reported a position in PVLA in Q1 2020 and held it in 15 quarters. The position peaked at $1.88M in Q3 2021. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.
- Sigma Planning reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
- Sigma Planning sold 6,500 Palvella Therapeutics shares in Q1 2026, an estimated $680K.
- Sigma Planning first reported a position in Palvella Therapeutics in Q1 2020 and held it in 15 quarters.
- Sigma Planning's Palvella Therapeutics position peaked at $1.88M in Q3 2021.
- 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.
Based on Sigma Planning's 13F filing for Q1 2026, filed 4 May 2026.